In the next installment of our brain health blog series, we will be reviewing the new research presented at the International Carotenoids Society‘s (ICS) symposium. The 18th ICS Symposium was a five day long event in Switzerland, hosting over 80 talks to almost 300 attendees. One topic of particular interest was the role of macular carotenoids, particularly lutein, in the brain. The benefits of lutein for the eyes are well documented, but emerging science is highlighting uses for cognitive health too. A variety of new studies on the subject were presented at the symposium by various speakers.
Lutein and zeaxanthin supplementation may slow progression of age-related macular degeneration and save EU billions in healthcare costs
Eye health is a leading health concern worldwide and, with 17.1 million people across the European Union (EU) alone suffering from age-related macular degeneration (AMD), it is clear to see why.1 AMD is a progressive degenerative eye disease and one of the main causes of vision loss.2 It affects the central vision, leaving those affected unable to see well directly ahead of them and potentially leading to a loss of independence and an inability to perform daily tasks. However, a new study by Frost & Sullivan has found that a daily consumption of 10mg of lutein and 2mg of zeaxanthin may help to slow the progression of AMD – increasing the health of the population and offering significant savings in public spending.